Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1Benjamin Besse, Anne Madroszyk, Federico Cappuzzo et al.|Annals of Oncology|2023Cited by 69
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|ESMO Open|2021Cited by 12
Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|Research Square|2020Cited by 1